American Journal of Nephrology · 2013 · 13 citations · 17 references
MedicineGeneticsNephrologyGenetic EpidemiologyHuman GeneticsMedical GeneticsChronic Kidney DiseaseGenetic RiskGenetic SusceptibilityHereditary Kidney DiseasesHereditary Renal DiseasesRenal DiseaseAccess To Genetic Test ResultsChronic Kidney Disease DisparitiesFisher’s Exact TestGenetic Test UtilizationGenetic TestingGenetic Testing Of At-risk RelativesKidney DiseasesReturn Of Genetic Results
BACKGROUND: Population ancestry-based differences exist in genetic risk for many kidney diseases. Substantial debate remains regarding returning genetic test results to participants. African-Americans (AAs) and European-Americans (EAs) at risk for end-stage kidney disease were queried for views on the value and use of genetic testing in research. METHODS: A standardized survey regarding attitudes toward genetic testing was administered to 130 individuals (64 AA, 66 EA) with first-degree relatives on dialysis. Fisher's exact test was used to assess differences in participant attitudes between population groups. RESULTS: Mean (SD) age of surveyed AAs and EAs was 45.5 (12.8) and 50.5 (14.4) years, respectively (p = 0.04), with similar familial relationships (p = 0.22). AAs and EAs wished to know their test results if risk could be: (1) reduced by diet or exercise (100 and 98%, p = 0.99); (2) reduced by medical treatment (100 and 98%, p = 0.99), or (3) if no treatments were available (90 and 82%, p = 0.21). If informed they lacked a disease susceptibility variant, 87% of AAs and 88% of EAs would be extremely or pretty likely to inform family members (p = 0.84). If informed they had a disease susceptibility variant, 92% of AAs and 89% of EAs would be extremely or pretty likely to inform their family (p = 0.43). CONCLUSIONS: Attitudes toward obtaining and using genetic test results for disease in research contexts were similar in AAs and EAs at risk for end-stage kidney disease. A substantial majority would want information regardless of available treatments and would share the information with the family. These results have important implications for patient care, study design and the informed consent process.
17
Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans
Giulio Genovese, David J. Friedman, Michael D. Ross et al. · Science · 2010 · 2K citations · Full text
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis
Jeffrey B. Kopp, Michael W. Smith, George W. Nelson et al. · Nature Genetics · 2008 · 708 citations
MYH9 is associated with nondiabetic end-stage renal disease in African Americans
W.H. Linda Kao, Michael J. Klag, Lucy A. Meoni et al. · Nature Genetics · 2008 · 648 citations · Full text
Medicine, Endocrinology, Nephrology +12